Articles related to BIOMARKERS

“By comparing current standard-of-care treatments with a potential novel therapy in refractory mCRC, this review underscores existing gaps and highlights future research priorities while awaiting randomized data.” – Elisabetta Bengala, MD, Regina Elena National Cancer Institute, Rome, Italy

The study authors concluded, “These findings further our understanding of shared and distinct neural mechanisms underlying mood disorders and assist in differential diagnosis, thereby guiding more accurate treatment strategies.”

The 2024 McDonald criteria continue to emphasize the importance of considering differential diagnoses, including reevaluating the diagnosis periodically over the disease course, even after a diagnosis of MS has been made.

“Disruption to the glymphatic system is likely to impair our ability to clear the brain of the amyloid and tau that causes Alzheimer’s disease.” — Hui Hong, University of Cambridge

“The results demonstrate robust effect sizes and good classification accuracy, which are needed for this assay to be adopted and widely used in the early detection and monitoring of AD.”

“Real-world driving behavior appears to be a promising digital biomarker for detecting early cognitive impairment. These subtle, progressive changes in mobility and driving patterns may help clinicians identify emerging cognitive impairment earlier, guide decisions around driving safety, and support timely interventions to preserve independence and mobility in aging adults.” – Neurologist Mill Etienne, MD